Use of Chemoprophylaxis to Prevent the Spread ofHemophilus influenzaeb in Day-Care Facilities

Publisher Website
Google Scholar
Abstract
Should children in day-care facilities receive rifampin chemoprophylaxis after the occurrence of invasive Hemophilus influenzae b disease in a day-care contact? The magnitude of uncertainty regarding the answer to this question can be gauged by the change in the American Academy of Pediatrics' recommendations on the use of rifampin.1 This change and the resulting differences between the recommendations of the Academy and those of the Immunization Practices Advisory Committee (ACIP) of the Centers for Disease Control, U.S. Public Health Service,2 have confused practicing physicians, making it difficult for state and local health departments to achieve consensus in the medical community . . .